Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry.
about
Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysisDiastolic dysfunctionRanolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivitySex differences in cardiovascular disease - Impact on care and outcomes.Prevalence and Risk Factors of Heart Failure with Preserved Ejection Fraction: A Population-Based Study in Northeast China.Chronic heart failure: contemporary diagnosis and management[Epidemiology of the relationship between atrial fibrillation and heart failure].Relation of beta-blocker use with frequency of hospitalization for heart failure in patients with left ventricular diastolic dysfunction (from the Heart and Soul Study)Beta-blockers in older patients with heart failure and preserved ejection fraction: class, dosage, and outcomes.Pharmacological Treatment of Heart Failure with Preserved Ejection FractionComparative effectiveness research in heart failure therapies: women, elderly patients, and patients with kidney diseaseROSE-AHF and lessons learned.Beta-blockers Associated with a Mortality Benefit in Patients with Systolic Dysfunction and Elevated Serum Bilirubin.Clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failureAtrial fibrillation in decompensated heart failure: associated factors and in-hospital outcome.Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatmentThe causes, consequences, and treatment of left or right heart failureTreatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm?Diagnosis and management of heart failure with preserved ejection fraction: 10 key lessonsDiastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum.Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: phase II results from the Pulmonary Artery Denervation-1 study.Incremental Reduction in Risk of Death Associated With Use of Guideline-Recommended Therapies in Patients With Heart Failure: A Nested Case-Control Analysis of IMPROVE HFHealth Literacy Mediates the Relationship Between Age and Health Outcomes in Patients With Heart FailureThe Prevention of Hospital Readmissions in Heart FailureComparison of β-blocker effectiveness in heart failure patients with preserved ejection fraction versus those with reduced ejection fraction.Influence of heart failure on the prognosis of patients with acute myocardial infarction in southwestern China.Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality MeasuresUse of guideline-recommended therapies for heart failure in the Medicare population.Pulmonary Hypertension in Heart Failure Patients Presenting at OAUTHC, Ile-Ife, Nigeria.Management of hypertension in chronic heart failure.Similarities and Differences between the Pathogenesis and Pathophysiology of Diastolic and Systolic Heart Failure.Heart rate as a treatable cardiovascular risk factor.Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failureDigoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure.Heart failure with preserved ejection fraction in the elderly: scope of the problem.Heart failure with preserved ejection fraction: pathophysiology and emerging therapies.Diagnosis and management of left ventricular diastolic dysfunction in the hypertensive patient.The dilemma, causes and approaches to avoid recurrent hospital readmissions for patients with chronic heart failure.Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes.Heart failure in hypertension: prevention and treatment.
P2860
Q21132299-AEA108E1-9257-4BA8-955D-DB3D03414D39Q28087715-127E8F1F-AC32-41B0-9D91-0C8B68346AC3Q28260201-052A9A91-C5A9-42FD-858F-0B351D31BE4EQ30234726-DA279823-0702-4493-BE5E-D550ED8F9532Q30375842-BF1E0E3E-C481-41F7-972F-070895111C7FQ33620431-D0B9E883-5376-46B8-B6F3-F12E1DF30214Q33676731-BE0EA89E-C9DA-4D80-8A57-7A7FF446880EQ33682749-CA214123-3EA5-4BD0-8513-F269D46AF1F2Q33857564-9DEABD0B-BC67-4C90-91B0-320F3C7E2B9DQ33885952-7D014F97-22A4-420C-A346-6653AF22B7F2Q34017388-AA0759BE-7573-48DC-A59F-4D5EEB32EEB1Q34117741-92553DF8-16B4-4832-AA73-0391775B0954Q34211025-57B2ECFF-34C9-4EA6-A59B-85174CC08C97Q34386568-20179F93-0C75-44B2-89FE-29B440A749E4Q34387849-78302133-839D-4FCF-A4A4-749AF320CA16Q34664894-530CF4AB-EDCF-4508-AE2C-5944F547C747Q34987168-70215AFA-2BFE-4744-8C74-0C4871017332Q35016271-44B5635E-06E4-432F-9D62-91561A3C47A0Q35139959-D0C42861-B79F-47B1-B601-A56A17E36591Q36167458-2C6FAF19-B8A7-4C42-BEB7-47AC1E03A0F5Q36287916-27F37180-B714-48A3-A7A9-0B4735BB82F4Q36366123-09069082-EA8C-4FED-A75F-E2D97518BA88Q36424089-4003B157-F55F-4BBB-BB9E-573CC87107E5Q36665264-1A44D308-2DAE-4FB0-81DF-A3C823C887D1Q36918171-1278484F-37B1-42F7-BEF8-7A7A82DA5EEDQ36953607-DAB56C10-F189-4724-B3AD-901C015831DBQ37085456-878A8F05-4F6C-4156-A654-B876B0F36251Q37087394-2B0E41C9-9E6A-47B4-86B0-8CF274708586Q37409709-A891CE0D-A00B-4E62-A8D7-447F7CD3AAD8Q37451537-C3CC7602-0AF4-4A0C-B951-DACD0062746AQ37477647-3B2EEE13-7F90-4179-9DCD-18E392BE8816Q37497745-3258C91D-CF02-4E64-A46D-8F0E7B6C5971Q37594550-F67A8E1C-9859-4BE5-9BFB-F0F94727EDFCQ37599290-F87B9593-A5C8-4A28-9794-06E62C69D0A2Q37633991-E9B95267-29AA-4727-8E96-634FBD0D872CQ37725106-68A7765C-8650-400D-BCE7-4EE44B13B9FCQ37821746-11F1EBF0-A448-41D7-8D9D-F9D2066DC70CQ37885271-A8639924-479C-4D68-80B1-42CEBAA903DCQ37889518-0B30EF7F-E79D-47EE-A622-544D46B07FB7Q38022713-47603E68-FFF0-40F2-9874-99165CF1F647
P2860
Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Clinical effectiveness of beta ...... with Heart Failure) Registry.
@ast
Clinical effectiveness of beta ...... with Heart Failure) Registry.
@en
type
label
Clinical effectiveness of beta ...... with Heart Failure) Registry.
@ast
Clinical effectiveness of beta ...... with Heart Failure) Registry.
@en
prefLabel
Clinical effectiveness of beta ...... with Heart Failure) Registry.
@ast
Clinical effectiveness of beta ...... with Heart Failure) Registry.
@en
P2093
P2860
P50
P921
P1476
Clinical effectiveness of beta ...... with Heart Failure) Registry.
@en
P2093
Bradley G Hammill
Kevin A Schulman
Lesley H Curtis
P2860
P304
P356
10.1016/J.JACC.2008.09.031
P407
P577
2009-01-01T00:00:00Z